Compare · head to head
AstraZeneca vs Novartis
AstraZeneca ranks higher overall — 360 rank 67 vs 38.
Novartis leads on Value (51 vs 43). AstraZeneca leads on Growth (58 vs 37), Safety (55 vs 44) and Sentiment (49 vs 39). The two are close on Quality.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | UK | Switzerland |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | XX-Large | XX-Large |
| ISIN | GB0009895292 | CH0012005267 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 67 | 38 |
| Value | 43 | 51 |
| Quality | 62 | 65 |
| Growth | 58 | 37 |
| Safety | 55 | 44 |
| Sentiment | 49 | 39 |
| Quality details | ||
| Profitability | 69 | 76 |
| Cash Truth | 55 | 55 |
AstraZeneca vs GlaxoSmithKline PharmaceuticalsAstraZeneca vs RocheAstraZeneca vs OrionAstraZeneca vs Laboratorios Farmaceuticos RoviAdd a third stock →
Full analyses: AstraZeneca · Novartis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100